ArticleResearch and practice in thrombosis and haemostasis2025
Andexanet alfa for the reversal of the low-molecular-weight heparin enoxaparin.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Andexanet alfa (andexanet) is the only approved reversal agent for patients with acute major bleeding during apixaban or rivaroxaban treatment. Its mechanism suggests it may also reverse the effects of low-molecular-weight heparin. Aim: To evaluate the effects of andexanet in healthy volunteers and in patients with acute major bleeding on enoxaparin. Methods: In the first study, healthy volunteers received enoxaparin 1 mg/kg twice daily for ≥3 doses and were randomized to receive either andexanet or placebo in high- or low-dose regimens, given 3 hours (high dose) or 8 hours (low dose) after the last dose. In the second study (Andexanet Alfa, a Novel Antidote to the Anticoagulant Effects of FXa Inhibitors 4), dosing depended on timing and amount of last enoxaparin dose: high dose if > 40 mg or <8 hours since last dose (or unknown), low dose if ≤ 40 mg or ≥8 hours. The high dose consisted of an 800 mg bolus followed by 960 mg >2 hours, while low dose consisted of a 400 mg bolus followed by 480 mg >2 hours. The primary outcome was change in anti-Xa activity. Hemostatic efficacy was assessed in patients with confirmed bleeding and baseline anti-Xa ≥ 0.25 IU/mL. Results: In the first study, 24 volunteers received andexanet (12 at a high dose and 12 at a low dose), and 7 received a placebo. Median anti-Xa activity decreased by 83% (0.92-0.17 IU/mL) in the high-dose cohort, and by 73% (0.78-0.22 IU/mL) in the low-dose cohort. In the second study, 22 patients received andexanet; anti-Xa activity decreased by 75% (95% CI, 67%-79%; 0.48-0.14 IU/mL). Good/excellent hemostasis was achieved in 14 of 16 assessable patients (88%). Conclusion: In enoxaparin-treated subjects, andexanet reduced anti-Xa activity and achieved effective hemostasis in 88% of patients. Results align with findings of patients using apixaban, rivaroxaban, or edoxaban.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.